PD-1 axis inhibitors in EGFR and ALK Driven Lung Cancer: Lost cause?

Ítems similars

• Perfect ALKemy: Optimizing the Use of ALK-Directed Therapies in Lung Cancer
  per: Politi, Katerina, et al.
  Publicat: (2014)
• Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non–Small Cell Lung Cancer
  per: Gettinger, Scott N., et al.
  Publicat: (2018)
• A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors
  per: Sasaki, Takaaki, et al.
  Publicat: (2011)
• Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR
  per: Narayanan, Dilip, et al.
  Publicat: (2017)
• Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer
  per: Kim, Su-Jung, et al.
  Publicat: (2019)